Home / Company / Our Business

DanioLabs (Cambridge, UK), is a therapeutics company that has two primary business streams:

1. Phenotypic evaluation of compounds for other organisations, either for activity effects, or for pre clinical safety pharmacology
2. Internal R&D investigating new users forestablished drugs (Reprofiling)

As part of our approach, we use zebrafish as a key enabling technology. Zebrafish as an experimental species provides significant benefits in the drug discovery process. They produce tiny, transparent offspring, that share some significant physiological and pharmacological similarities to humans, not least that they are vertebrates. Their size allows them to be used to evaluate the effects of compounds in human disease models in 96 well plate format. Therefore, high-throughput in-vivo assays are possible.

Working with other Companies:

Daniolables undertakes both revenue generating and risk-sharing collaborations with other drug discovery organisations. We work with our partner companies to:

1. Develop new disease models
2. Screen compounds for activity
3. Evaluation compounds for safety pharmacology
4. Undertake target validation studies.

We welcome the opportunity to discuss our approach with potential partner companies.

DanioLabs' Internal R&D

With a focus upon neurological and ophthamological diseases, the Company uses their proprietary in vivo screening technology to look for new uses for established drugs - or for dugs that have failed in clinical development - either as single entities or in novel combinations to identify new and protectable uses. Active compounds from our screening programmes are selected and developed into new therapeutics. DanioLabs will out-licence development compounds in either pre-clinical or clinical development stages.